ASX Share rice
Mon 17 May 2021 - 10:02:am (Sydney)

1AD Share Price

ADALTA LIMITED1ADPharmaceuticals, Biotechnology & Life Sciences

1AD Company Information

Name:

AdAlta Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

2 Park Drive Bundoora VIC Australia 3083

Phone:

61 3 9479 5159

CEO, MD & Director:

Dr. Timothy Charles Oldham B.Sc., L.L.B., BSc(Hons), LLB(Hons), Ph.D.

Chief Operating Officer:

Dr. Dallas Hartman

Chief Scientific Advisor & Chief Scientific Officer:

Prof. Michael Foley Ph.D.

Company Sec.:

Mr. Cameron Jones C.A.

Company Overview:

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with GE Healthcare to discover i-bodies against granzyme B for use as a molecular imaging agent. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.

1AD Share Price Information

Shares Issued:

245.18M

Market Capitalisation:

$33.10M

Revenue (TTM):

$4.23M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.05

Profit Margin:

-1.0668

Operating Margin (TTM):

$-0.97

Return On Assets (TTM):

$-0.37

Return On Equity (TTM):

$-0.85

Quarterly Revenue Growth (YOY):

0.995

Gross Profit(TTM):

$-3,354,798

Diluted Earnings Per Share (TTM):

$-0.024

1AD CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-2,376

Change To Liabilities:

$-910,253

Total Cashflow From Investing Activities:

$-2,376

Net Borrowings:

$2.08M

Net Income:

$-6,006,456

Total Cash From Operating Activities:

$-5,889,212

Depreciation:

$41.83K

Change To Account Receivables:

$249.05K

Sale Purchase Of Stock:

$1.78M

Capital Expenditures:

$2.38K

1AD Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-6,006,460

Net Income:

$-6,006,460

Gross Profit:

$-3,165,360

Operating Income:

$-5,820,710

Other Operating Expenses:

$757.98K

Interest Expense:

$115.55K

Total Revenue:

$3.85M

Cost Of Revenue:

$7.01M

1AD Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$3.21M

Total Stockholder Equity:

$3.70M

Other Current Liabilities:

$174.72K

Total Assets:

$6.91M

Common Stock:

$28.44M

Retained Earnings:

$-25,598,412

Other Liabilities:

$1

Other Assets:

$77.92K

Cash:

$3.37M

Total Current Liabilities:

$3.21M

Short-Term Debt:

$2.19M

Property - Plant & Equipment:

$98.65K

Net Tangible Assets:

$3.70M

Long-Term Investments:

$77.92K

Total Current Assets:

$6.73M

Net Receivables:

$3.31M

Short-Term Investments:

$176.57K

Accounts Payable:

$540.83K

Short-Term Investments:

$176.57

Non Current Liabilities Total:

$0

1AD Share Price History

1AD News

26 Feb, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
04 Jan, 2021
Melbourne, Australia--(Newsfile Corp. - January 4, 2021) - AdAlta Limited (ASX: 1AD), a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets is pleased to announce it is presenting at Biotech Showcase™ 2021, which is being held in a virtual format from 11-15 January 2021.Biotech Showcase is an investor and partnering conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and ...
17 Aug, 2020
With the business potentially at an important milestone, we thought we'd take a closer look at AdAlta Limited's...